186 related articles for article (PubMed ID: 37644118)
1. In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody.
Rattanapisit K; Bulaon CJI; Strasser R; Sun H; Phoolcharoen W
Sci Rep; 2023 Aug; 13(1):14146. PubMed ID: 37644118
[TBL] [Abstract][Full Text] [Related]
2. Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition.
Phetphoung T; Malla A; Rattanapisit K; Pisuttinusart N; Damrongyot N; Joyjamras K; Chanvorachote P; Phakham T; Wongtangprasert T; Strasser R; Chaotham C; Phoolcharoen W
PLoS One; 2022; 17(11):e0274737. PubMed ID: 36367857
[TBL] [Abstract][Full Text] [Related]
3. Development of Plant-Derived Bispecific Monoclonal Antibody Targeting PD-L1 and CTLA-4 against Mouse Colorectal Cancer.
Bulaon CJI; Khorattanakulchai N; Rattanapisit K; Sun H; Pisuttinusart N; Phoolcharoen W
Planta Med; 2024 Apr; 90(4):305-315. PubMed ID: 38373705
[TBL] [Abstract][Full Text] [Related]
4. De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.
Ou-Yang F; Li CL; Chen CC; Shen YC; Moi SH; Luo CW; Xia WY; Wang YN; Lee HH; Wang LH; Wang SC; Pan MR; Hou MF; Hung MC
Am J Cancer Res; 2022; 12(1):123-137. PubMed ID: 35141008
[TBL] [Abstract][Full Text] [Related]
5. Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody.
Rattanapisit K; Phakham T; Buranapraditkun S; Siriwattananon K; Boonkrai C; Pisitkun T; Hirankarn N; Strasser R; Abe Y; Phoolcharoen W
Sci Rep; 2019 Oct; 9(1):15205. PubMed ID: 31645587
[TBL] [Abstract][Full Text] [Related]
6. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
[TBL] [Abstract][Full Text] [Related]
7. Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.
Mabbitt J; Holyer ID; Roper JA; Nilsson UJ; Zetterberg FR; Vuong L; Mackinnon AC; Pedersen A; Slack RJ
Front Immunol; 2023; 14():1250559. PubMed ID: 37701441
[TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
Araujo-Fernandez I; Delgado J; Moscetti L; Sarac SB; Zander H; Mueller-Egert S; Dunder K; Pean E; Bergmann L; Enzmann H; Pignatti F
ESMO Open; 2021 Feb; 6(1):100008. PubMed ID: 33399074
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
[TBL] [Abstract][Full Text] [Related]
10. Functional Characterization of Pembrolizumab Produced in
Phakham T; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Buranapraditkun S; Boonkrai C; Sooksai S; Hirankarn N; Abe Y; Strasser R; Rattanapisit K; Phoolcharoen W
Front Plant Sci; 2021; 12():736299. PubMed ID: 34567049
[TBL] [Abstract][Full Text] [Related]
11. Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation.
Xiao D; Luo L; Li J; Wang Z; Liu L; Xie F; Feng J; Zhou X
Bioorg Chem; 2021 Nov; 116():105366. PubMed ID: 34560561
[TBL] [Abstract][Full Text] [Related]
12. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
[TBL] [Abstract][Full Text] [Related]
14. Investigation of a monoclonal antibody against enterotoxigenic
Teh AY; Cavacini L; Hu Y; Kumru OS; Xiong J; Bolick DT; Joshi SB; Grünwald-Gruber C; Altmann F; Klempner M; Guerrant RL; Volkin DB; Wang Y; Ma JK
Gut Microbes; 2021; 13(1):1-14. PubMed ID: 33439092
[TBL] [Abstract][Full Text] [Related]
15. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.
Tuli HS; Garg VK; Choudhary R; Iqubal A; Sak K; Saini AK; Saini RV; Vashishth K; Dhama K; Mohapatra RK; Gupta DS; Kaur G
Mol Biol Rep; 2023 Mar; 50(3):2685-2700. PubMed ID: 36534236
[TBL] [Abstract][Full Text] [Related]
17. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
Fujita K; Uchida N; Yamamoto Y; Kanai O; Okamura M; Nakatani K; Sawai S; Mio T
Anticancer Res; 2019 Jul; 39(7):3917-3921. PubMed ID: 31262921
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Seto T; Nosaki K; Shimokawa M; Toyozawa R; Sugawara S; Hayashi H; Murakami H; Kato T; Niho S; Saka H; Oki M; Yoshioka H; Okamoto I; Daga H; Azuma K; Tanaka H; Nishino K; Tohnai R; Yamamoto N; Nakagawa K
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105689
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
Inman BA; Longo TA; Ramalingam S; Harrison MR
Clin Cancer Res; 2017 Apr; 23(8):1886-1890. PubMed ID: 27903674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
